Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress

Endothelial dysfunction, induced by oxidative stress, is an essential factor affecting cardiovascular disease. Uncoupling of endothelial nitric oxide synthase (eNOS) leads to a decrease in nitric oxide (NO) production, an increase in reactive oxygen species (ROS) production, NO consumption, and NO synthesis. As a main active ingredient of astragalus, astragaloside IV can reduce the apoptosis of endothelial cells during oxidative stress. This review is aimed at exploring the mechanism of astragaloside IV in improving oxidative stress-mediated endothelial dysfunction relevant to cardiovascular diseases. The findings showed that the astragaloside IV can prevent or reverse the uncoupling of eNOS, increase eNOS and NO, and enhance several activating enzymes to activate the antioxidant system. In-depth validation and quantitative experiments still need to be implemented.

[1]  T. Myöhänen,et al.  Prolyl Oligopeptidase Inhibition Reduces Oxidative Stress via Reducing NADPH Oxidase Activity by Activating Protein Phosphatase 2A. , 2021, Free radical biology & medicine.

[2]  Xiaozhi Liu,et al.  Astragaloside IV improves angiogenesis under hypoxic conditions by enhancing hypoxia-inducible factor-1α SUMOylation , 2021, Molecular medicine reports.

[3]  I. Gregoric,et al.  Endothelial Dysfunction and Its Clinical Implications , 2021, Angiology.

[4]  Ling Zhang,et al.  Protective Effect of Astragaloside IV on High Glucose-Induced Endothelial Dysfunction via Inhibition of P2X7R Dependent P38 MAPK Signaling Pathway , 2020, Oxidative medicine and cellular longevity.

[5]  Jun Li,et al.  Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases , 2020, Drug design, development and therapy.

[6]  M. Scioli,et al.  Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets , 2020, Journal of clinical medicine.

[7]  Xuelei Zhang,et al.  Astragaloside IV relieves gestational diabetes mellitus in genetic mice through reducing hepatic gluconeogenesis. , 2020, Canadian journal of physiology and pharmacology.

[8]  Chen Wei,et al.  Astragaloside IV Protects Against Oxidative Stress in Calf Small Intestine Epithelial Cells via NFE2L2-Antioxidant Response Element Signaling , 2019, International journal of molecular sciences.

[9]  Li-ping Zhu,et al.  Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation. , 2019, Life sciences.

[10]  W. Dichtl,et al.  Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? , 2019, Nutrients.

[11]  J. L. La Favor,et al.  Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? , 2019, International journal of molecular sciences.

[12]  J. T. Afshari,et al.  Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease. , 2019, Atherosclerosis.

[13]  Qiang Wu,et al.  Astragaloside IV promotes the eNOS/NO/cGMP pathway and improves left ventricular diastolic function in rats with metabolic syndrome , 2019, The Journal of international medical research.

[14]  Guo-ming Shen,et al.  Astragaloside IV prevents high glucose-induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells , 2019, Molecular medicine reports.

[15]  Jiekun Luo,et al.  Astragaloside IV Improves Vasodilatation Function by Regulating the PI3K/Akt/eNOS Signaling Pathway in Rat Aorta Endothelial Cells , 2018, Journal of Vascular Research.

[16]  Chao Xu,et al.  Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice , 2018, Front. Physiol..

[17]  Dufang Ma,et al.  Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance , 2018, Molecules and cells.

[18]  Xiao-zhong Peng,et al.  Astragaloside Ⅳ Protects Against Aβ1-42-induced Oxidative Stress, Neuroinflammation and Cognitive Impairment in Rats. , 2018, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[19]  A. Miyazaki,et al.  Dysregulation of Calpain Proteolytic Systems Underlies Degenerative Vascular Disorders , 2018, Journal of atherosclerosis and thrombosis.

[20]  U. Förstermann,et al.  Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis , 2017, Circulation research.

[21]  Meili Lu,et al.  Pretreatment with Astragaloside IV protects human umbilical vein endothelial cells from hydrogen peroxide induced oxidative stress and cell dysfunction via inhibiting eNOS uncoupling and NADPH oxidase - ROS - NF-κB pathway. , 2016, Canadian journal of physiology and pharmacology.

[22]  Di Yang,et al.  Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells , 2015, International journal of molecular medicine.

[23]  Yan Gao,et al.  Protective effect of allicin on high glucose/hypoxia-induced aortic endothelial cells via reduction of oxidative stress , 2015, Experimental and therapeutic medicine.

[24]  L. Liao,et al.  The protective effect of astragaloside IV against benzo[a]pyrene induced endothelial progenitor cell dysfunction. , 2015, Life sciences.

[25]  Younan Chen,et al.  The role of Nrf2 in oxidative stress-induced endothelial injuries. , 2015, The Journal of endocrinology.

[26]  Y. Keum,et al.  Molecular and Chemical Regulation of the Keap1-Nrf2 Signaling Pathway , 2014, Molecules.

[27]  T. Finkel,et al.  Cellular mechanisms and physiological consequences of redox-dependent signalling , 2014, Nature Reviews Molecular Cell Biology.

[28]  Amir Lerman,et al.  Endothelial dysfunction over the course of coronary artery disease. , 2013, European Heart Journal.

[29]  Chuanhua Yang,et al.  Astragaloside IV Stimulates Angiogenesis and Increases Nitric Oxide Accumulation via JAK2/STAT3 and ERK1/2 Pathway , 2013, Molecules.

[30]  Ping Liu,et al.  Pharmacological effects of Astragaloside IV: a literature review. , 2013, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[31]  L. Liao,et al.  Benzo[a]pyrene induces oxidative stress and endothelial progenitor cell dysfunction via the activation of the NF-κB pathway. , 2013, International journal of molecular medicine.

[32]  M. Kirsch,et al.  JAK2-STAT3 signaling , 2012, JAK-STAT.

[33]  Hong Li,et al.  Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells , 2012, Cardiovascular Diabetology.

[34]  G. Gao,et al.  Astragaloside IV prevents MPP+-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production , 2012, Molecular and Cellular Biochemistry.

[35]  T. Münzel,et al.  Is oxidative stress a therapeutic target in cardiovascular disease? , 2010, European heart journal.

[36]  Wen Gao,et al.  Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics , 2010 .

[37]  Xian-ji Xie,et al.  Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. , 2010, Biological & pharmaceutical bulletin.

[38]  U. Förstermann.  Nitric oxide and oxidative stress in vascular disease , 2010, Pflügers Archiv - European Journal of Physiology.

[39]  L. Ghiadoni,et al.  Human endothelial dysfunction: EDCFs , 2010, Pflügers Archiv - European Journal of Physiology.

[40]  T. Münzel,et al.  Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. , 2008, Antioxidants & redox signaling.

[41]  ThomasMünzel,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease , 2006 .

[42]  G. Jackson.  Endothelial function and dysfunction , 2004, International journal of clinical practice.

[43]  P. Poredos,et al.  Endothelial dysfunction and cardiovascular disease , 2002, Pathophysiology of Haemostasis and Thrombosis.

[44]  R. Mittler.  Oxidative stress, antioxidants and stress tolerance. , 2002, Trends in plant science.

[45]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[46]  B. Halliwell.  Reactive oxygen species in living systems: source, biochemistry, and role in human disease. , 1991, The American journal of medicine.

[47]  H. Shimokawa,et al.  Endothelial Functions. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[48]  Jiayi Cai,et al.  Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. , 2014, Chemical & pharmaceutical bulletin.

[49]  M. Kirsch,et al.  JAK 2-STAT 3 signaling A novel function and a novel mechanism , 2012 .

[50]  H. Buttar,et al.  Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. , 2005, Experimental and clinical cardiology.

[51]  T. Malinski,et al.  Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. , 2004, Acta biochimica Polonica.